New med for depression
Note: this article is provided by Ohio Northern University Healthwise Pharmacy.
Esketamine is considered the first big depression advance since the approval of Prozac — and it just got approved.
Dozens of antidepressants have been approved over the years. These include Eli Lilly’s “blockbuster” drug Prozac, which was approved in 1987. But there haven't been any new advancements in other types of antidepressants that work in different ways.
Spravato (esketamine), a nasal spray to treat treatment-resistant depression, offers the first new mechanism of action in 30 years to treat major depressive disorder (MDD).
Currently, esketamine is believed to work differently than the current antidepressants available on the market.
The FDA approved it to treat depression in adults who have tried at least two antidepressant medicines (taken for a good amount of time) that did not work. This suggests that these adults have treatment-resistant depression. Esketamine is to be given with another oral antidepressant (taken by mouth).
Esketamine is available in a 28-milligram, single-use nasal spray.
Johnson & Johnson’s esketamine is very close in structure to ketamine, which is known as a psychedelic club drug. This medication is only available through a restricted distribution system under a Risk Evaluation and Mitigation Strategy (REMS). That's because this medication may cause serious side effects, such as drowsiness and disassociation (a sense of being detached from yourself and your emotions). There is also a potential for abuse and misuse of this medication:
- Those who receive this medication are to be monitored for two hours after the dose is given.
- This medication will not be dispensed directly to patients. Instead, it will only be given in certified medical offices and settings.
- Patients will be enrolled in a registry.
The patient is required to sign a Patient Enrollment Form to acknowledge that they understand they need to make arrangements to safely leave the medical office to get home. They also have to certify that they know they can't drive or use heavy machinery for the rest of the day.
Other potentially serious side effects tied to esketamine include suicidal thoughts and behaviors. These potential effects are noted in esketamine's boxed warning (the strongest medication warning). Dizziness, nausea, increased blood pressure, vomiting and feeling drunk are among this medication's other potential side effects.
Esketamine's approval was granted to Janssen Pharmaceuticals, Inc.
Stories Posted This Week
Saturday, October 17, 2026
Friday, October 16, 2026
- Production offers a modern take on the story of St. Clare of Assisi
- Bluffton volleyball edged in 5 by Van Buren
- Pirate girls soccer tie O-G
- October 16 Bluffton Schools athletics lineup, streaming
- Bluffton Council recap: Officers honored for 25 years of service
- Bluffton Clean Up teams up with Troop 3256 Cub Scouts
- Ada FFA: Feeding the Farmers
- Nov. 7 Fall Community Day at Bluffton University
- Quarry Farm Nature Preserve news for Fall 2026
Thursday, October 15, 2026
- DeWine announces $200M Rural Health Transformation program award
- Herb program with Marge Lafollette, Oct. 15
- Prairie seeding activity at Bluffton University, October 24
- Food for thought: Choline for the brain
- Results for 5K on October 2, Bluffton University Homecoming event
- 15 minutes with Sherry Miller, senior center activities coordinator
Wednesday, October 14, 2026
- Ada Icon headlines, October 14
- CANCELLED Main St. closure on October 15
- Frederick Clyde Warren founded True-2-Form Plastics
- Pirate boys soccer beats Wapak in regular season finale
- Pirate girls soccer defeats Liberty Center
- Mennonite pastor to explore ‘good news’ in creation
- Bluffton University earns recognition in U.S. News & World Report rankings
- Obituary for Deborah "Debbie" Welch, 74
- Spirits and exorcism presentation during University Spiritual Life Week Forum
- Dodging bullets: Bluffton oral history 90+ years after Dillinger robbery
- Nora Matthews named BHS Student of the Month for September 2026
- ICAPP analysis on charter status and local autonomy
Tuesday, October 13, 2026
- Ada Icon headlines, October 13
- Bluffton area Women in Business meeting October 15
- Leo club glasses collection
- Night at the (Swiss Historical) Museum, October 24
- Woodcarving ornament workshop at Swiss Heritage Center
- Barefoot nature walks at the Nature Preserve
- Pirate volleyball seeded 4th
- Beavers sports roundup, October 6-11
- Bluffton leaf pickup scheduled for last week of October
- Pirate boys soccer shuts out Bellefontaine
- Watch an after school movie at the Bluffton Public Library
- Dunlap awarded OSBA humanitarian award